Participate in an Alzheimer’s Research Study
If you or someone you love is experiencing memory loss, or has been diagnosed with Alzheimer’s disease, perhaps you should consider participating in a clinical research study. Participants receive a high standard of care, and research shows that people involved in clinical trials tend to do somewhat better than people in a similar stage of their disease who are not enrolled in clinical trials.*
Health insurance is not necessary to participate. Patients who qualify for our clinical trials will receive all study related care and treatment at no cost. In some cases you may be compensated for your time and travel. You may even gain access to research treatments before they are widely available.
Interested in learning about our Alzheimer’s research studies? Contact the Premiere Research Institute of Palm Beach by calling (561) 296-3824 or fill out the form below.
Perhaps the best reason to participate in an Alzheimer’s clinical trial is so that you can take an active role in your health care, by educating yourself regarding your condition. You will obtain access to top quality medical care from our Board Certified physicians at a medical research healthcare facility specializing in Alzheimer’s care.
Without volunteers for clinical trials, improved treatments, including a cure for Alzheimer’s disease can never become a reality.
Premiere Research Institute is currently seeking volunteers for the LAURIET Study.
What is the LAURIET study?
The LAURIET Study from Genentech will test how safe the investigational medication is and whether it works in affecting Alzheimer’s Disease. The study will also use imaging (using a scanner to make a detailed picture) to look at how the investigational medication affects certain substances in the brain.
Some patients in the study will receive a placebo (which looks the same as the investigational medication but contains no actual medication). Other people will receive the investigational medication. This way the researchers can see if there is any difference in effect between people receiving the investigational medication and people receiving placebo. You will have a 50% chance (1 in 2) of receiving the investigational medication and a 50% chance of receiving placebo.
Who can take part?
You may be able to take part in the LAURIET Study if you are 50 to 85 years of age with moderate Alzheimer’s Disease (for example, confusion about dates and locations, difficulty recalling important events, and needing help with dressing). You need somebody who can be a reliable study partner or caregiver and who can come to some study visits with you and answer questions about your health.
Click here for more information
Articles about Alzheimer’s Disease
To read one of our most recent articles about Alzheimer’s Disease just click the title of the article.
In recent years, there has been a growing body of research dedicated to determining ways to improve and maintain cognitive function through the aging process, particularly late in life. It is currently estimated that at least 20% of older adults encounter a...read more
A new, innovative non-invasive eye scan for Alzheimer's may be able to detect the disease in a matter of seconds, according to the findings of two recent studies. Moreover, this new diagnostic technology may be able to catch the disease early in people who are...read more
Insufficient or poor-quality sleep may increase the risk of developing Alzheimer’s disease, according to a health advisory from the American Academy of Sleep Medicine (AASM). Their advisory is based on the results of epidemiological studies that have shown a possible...read more
New findings from a meta-analysis of studies involving over 11,000 individuals has strengthened the connection between physical exercise and benefits to cognition. Published in the journal Neurology Clinical Practice, this meta-analysis revealed improvements in...read more
Depression in older adults may be correlated with memory loss due to accelerated brain aging, according to the findings of a study published earlier this year in the journal Neurology. Based on the results of the study, which involved older adult subjects (mean age of...read more
A recent study examined whether beta-amyloid growth in cognitively normal older adults who are considered beta-amyloid negative (as opposed to beta-amyloid positive) experience symptoms of cognitive decline. Beta-amyloid is the protein component that forms the amyloid...read more
The FDA has recently approved the first blood test that indicates the presence of bleeding in the brain from mild traumatic brain injury (TBI). This new test is intended to identify certain patients who do not need imaging to determine whether they have intracranial...read more
Cognitive training exercises may be effective at improving or delaying age-related cognitive decline, according to a report from the National Academies of Science, Engineering, and Medicine (NASEM). The report examined a systematic review of randomized controlled...read more
A blood test that screens for the presence and buildup of amyloid plaques in the brain decades before the onset of Alzheimer’s symptoms could be a promising and widely accessible way to detect Alzheimer’s disease early. Studies have indicated that the pathology of...read more
Carl Sadowsky, M.D., FAAN Benefits of Controlling Blood Pressure Controlled blood pressure is advantageous to our overall health and longevity. In addition to providing benefits to our cardiovascular system, optimal blood pressure management also improves...read more